# Trial of CHOP versus CIOP in Good Risk Stage II-IV Patients with Histologically Aggressive Non-Hodgkin's Lymphoma

Submission date	Recruitment status No longer recruiting	<ul><li>Prospectively registered</li></ul>		
19/08/2002		☐ Protocol		
Registration date	Overall study status	Statistical analysis plan		
19/08/2002	Completed	[X] Results		
Last Edited	Condition category	[] Individual participant data		
31/10/2019	Cancer			

## Plain English summary of protocol

Not provided at time of registration

# Contact information

## Type(s)

Scientific

#### Contact name

Dr - -

#### Contact details

UKCCCR Register Co-ordinator MRC Clinical Trials Unit 222 Euston Road London United Kingdom NW1 2DA

# Additional identifiers

# Protocol serial number

LY/GR

# Study information

#### Scientific Title

Trial of CHOP versus CIOP in Good Risk Stage II-IV Patients with Histologically Aggressive Non-Hodgkin's Lymphoma

#### **Study objectives**

Not provided at time of registration

#### Ethics approval required

Old ethics approval format

#### Ethics approval(s)

Not provided at time of registration

#### Study design

Randomised controlled trial

#### Primary study design

Interventional

#### Study type(s)

**Treatment** 

#### Health condition(s) or problem(s) studied

Lymphoma (non-Hodgkin's)

#### Interventions

Patients are randomised to one of two treatment regimens:

- 1. CHOP Regimen: Adriamycin, cyclophosphamide, vincristine and prednisone cycle repeated every 3 weeks. Chemotherapy to be given for two courses beyond complete remission and a minimum of six courses or until progression.
- 2. CIOP Regimen: Idiarubicin, cyclophosphamide, vincristine and prednisone cycle repeated every 3 weeks. Chemotherapy to be given for two courses beyond complete remission and a minimum of six courses or until progression.

#### Intervention Type

Drug

#### Phase

**Not Specified** 

#### Drug/device/biological/vaccine name(s)

Cocktail

## Primary outcome(s)

Not provided at time of registration

#### Key secondary outcome(s))

Not provided at time of registration

#### Completion date

14/07/1997

# **Eligibility**

#### Key inclusion criteria

- 1. Age 16-59 years
- 2. No medical conditions, other than lymphoma, prohibiting intensive therapy and no systemic treatment for cancer in previous 5 years
- 3. One of the following histological types:
- 3.1 Follicular large cell
- 3.2 Diffuse mixed cell
- 3.3 Diffuse large cell
- 3.4 Diffuse immunoblastic lymphomas
- 4. Full clinical staging to include Computed Tomography (CT) scanning of abdomen and bone marrow trephine biopsy
- 5. Good prognostic features defined as the presence of less than two of:
- 5.1 Stage III/IV
- 5.2 Lactic dehydrogenase (LDH) >normal
- 5.3 Eastern Cooperative Oncology Group (ECOG) or World Health Organisation (WHO) performance status 2-4

#### Participant type(s)

**Patient** 

#### Healthy volunteers allowed

No

#### Age group

Not Specified

#### Sex

**Not Specified** 

#### Total final enrolment

211

#### Kev exclusion criteria

Not provided at time of registration

#### Date of first enrolment

01/01/1995

#### Date of final enrolment

14/07/1997

# Locations

#### Countries of recruitment

**United Kingdom** 

England

#### Study participating centre

### UKCCCR Register Co-ordinator London United Kingdom NW1 2DA

# Sponsor information

## Organisation

British National Lymphoma Investigation (BNLI) (UK)

# Funder(s)

### Funder type

Research organisation

#### **Funder Name**

British National Lymphoma Investigation

# **Results and Publications**

Individual participant data (IPD) sharing plan

# IPD sharing plan summary

Not provided at time of registration

# **Study outputs**

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Results article	results	01/08/2005	31/10/2019	Yes	No